The study team engineered a standalone PD-1 chimeric switch receptor (CSR) T-cell platform aimed at preserving the antitumor benefits of PD-L1 targeting while lowering the risk of on-target/off-tumor toxicity. The investigators applied iterative receptor engineering. They evaluated antitumor activity and normal-cell reactivity as parallel selection criteria, rather than optimizing for potency alone. This dual-criterion approach produced two lead PD-1 CSR T-cell candidates chosen for their combination of tumor potency and relative safety signals in vitro.
Data indicated that, compared with the authors’ previously developed antibody-based PD-L1 CAR T cells, the two PD-1 CSR leads preserved potent PD-L1–specific cytotoxicity against tumor cells while demonstrating markedly reduced cytotoxicity against several primary human normal cell types. The normal cells tested included small airway epithelial cells, astrocytes, renal epithelial cells, hepatocytes, and cardiomyocytes. The authors reported reduced killing of those primary cells by the PD-1 CSR T cells, implying improved tumor–normal discrimination; the source did not provide quantitative percent-kill values in the abstract. The study team observed that the engineered PD-1 CSR T cells still targeted PD-L1–expressing cells but with an altered reactivity profile relative to antibody-based CAR T constructs.
Investigators evaluated activity against both tumor cells and immunosuppressive myeloid cells. The PD-1 CSR candidates efficiently eliminated PD-L1–positive immunosuppressive myeloid cells in vitro. They also mediated dual-compartment targeting—simultaneous engagement of tumor and myeloid populations—within three-dimensional multicellular tumor organoids. The organoid results signaled the platform’s capacity to address both malignant cells and TME-associated immune suppression, a feature the authors emphasized as preserved despite the reduced reactivity against normal tissue cell types.
The preclinical program included in vivo testing in two model systems. After systemic administration, PD-1 CSR T cells suppressed tumor growth in an orthotopic breast cancer model. Following intracranial administration, the same platform prolonged survival in a patient-derived glioblastoma model. The study team reported both tumor suppression and survival benefit with the lead candidates. The source did not report human clinical safety or efficacy data, nor did it present dosing regimens or detailed toxicity grading in the abstract, so those parameters remain unreported in this preprint.
Authors disclosed that H.Q., Y.L., A.Q.-H., and M.A.K.-D. are named inventors on a provisional patent application related to the PD1-CSR technology. Funding acknowledged in the source included the National Institute of Neurological Disorders and Stroke (R01 support listed), the Florida Health Grant, Florida State Casey DeSantis Cancer Research Funding, the Florida Cancer Innovation Fund, and the Georg Haub Family Career Development Award. The study team framed the PD-1 CSR approach as a standalone cellular therapy platform intended to expand the therapeutic window of PD-L1 targeting across solid tumors by preserving dual-compartment targeting while reducing normal-cell reactivity.
This preprint reports preclinical efficacy and selectivity signals but does not include clinical trial data. The source did not report human dosing, safety data, or regulatory filings beyond the noted provisional patent. Details on long-term persistence, potential immune-related adverse events in vivo beyond the described models, manufacturing scale-up, and comparator safety profiles in humans were not provided in the abstract. Those unanswered questions will need addressing before clinical translation, according to the authors’ stated intent to provide a foundation for further development.
The work documents a rational engineering path to separate tumor and normal-cell activity for PD-L1-targeted cellular therapy, while leaving key translational endpoints—clinical safety, dosing strategy, and regulatory milestones—unreported in this preprint.